PHF13 is a molecular reader and transcriptional co-regulator of H3K4me2/3

  1. Chung Ho-Ryun
  2. Chao Xu
  3. Alisa Fuchs
  4. Andreas Mund
  5. Martin Lange
  6. Hannah Staege
  7. Tobias Schubert
  8. Chuanbing Bian
  9. Ilona Dunkel
  10. Anton Eberharter
  11. Catherine Regnard
  12. Henrike Klinker
  13. David Meierhofer
  14. Luca Cozzuto
  15. Andreas Winterpacht
  16. Luciano DiCroce
  17. Jinrong Min
  18. Hans Will
  19. Sarah Kinkley  Is a corresponding author
  1. Max Planck Institute for Molecular Genetics, Germany
  2. Structural Genomics Consortium, Canada
  3. Heinrich-Pette-Institute - Leibniz Institute for Experimental Virology, Germany
  4. Bayer Pharma AG, Germany
  5. Ludwig-Maximilians-University, Germany
  6. Centre for Genomic Regulation, Spain
  7. Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany

Abstract

PHF13 is a chromatin affiliated protein with a functional role in differentiation, cell division, DNA damage response and higher chromatin order. To gain insight into PHF13's ability to modulate these processes, we elucidate the mechanisms targeting PHF13 to chromatin, its genome wide localization and its molecular chromatin context. Size exclusion chromatography, mass spectrometry, X-ray crystallography and ChIP sequencing demonstrate that PHF13 binds chromatin in a multivalent fashion via direct interactions with H3K4me2/3 and DNA, and indirectly via interactions with PRC2 and RNA PolII. Furthermore, PHF13 depletion disrupted the interactions between PRC2, RNA PolII S5P, H3K4me3 and H3K27me3 and resulted in the up and down regulation of genes functionally enriched in transcriptional regulation, DNA binding, cell cycle, differentiation and chromatin organization. Together our findings argue that PHF13 is an H3K4me2/3 molecular reader and transcriptional co-regulator, affording it the ability to impact different chromatin processes.

Article and author information

Author details

  1. Chung Ho-Ryun

    Max Planck Institute for Molecular Genetics, Berlin, Germany
    Competing interests
    The authors declare that no competing interests exist.
  2. Chao Xu

    Structural Genomics Consortium, Toronto, Canada
    Competing interests
    The authors declare that no competing interests exist.
  3. Alisa Fuchs

    Max Planck Institute for Molecular Genetics, Berlin, Germany
    Competing interests
    The authors declare that no competing interests exist.
  4. Andreas Mund

    Heinrich-Pette-Institute - Leibniz Institute for Experimental Virology, Hamburg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  5. Martin Lange

    TRG-ONCI, Bayer Pharma AG, Berlin, Germany
    Competing interests
    The authors declare that no competing interests exist.
  6. Hannah Staege

    Heinrich-Pette-Institute - Leibniz Institute for Experimental Virology, Hamburg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  7. Tobias Schubert

    Heinrich-Pette-Institute - Leibniz Institute for Experimental Virology, Hamburg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  8. Chuanbing Bian

    Structural Genomics Consortium, Toronto, Canada
    Competing interests
    The authors declare that no competing interests exist.
  9. Ilona Dunkel

    Max Planck Institute for Molecular Genetics, Berlin, Germany
    Competing interests
    The authors declare that no competing interests exist.
  10. Anton Eberharter

    Adolf-Butenandt-Institute and Center for Integrated Protein Science, Ludwig-Maximilians-University, Munich, Germany
    Competing interests
    The authors declare that no competing interests exist.
  11. Catherine Regnard

    Adolf-Butenandt-Institute and Center for Integrated Protein Science, Ludwig-Maximilians-University, Munich, Germany
    Competing interests
    The authors declare that no competing interests exist.
  12. Henrike Klinker

    Adolf-Butenandt-Institute and Center for Integrated Protein Science, Ludwig-Maximilians-University, Munich, Germany
    Competing interests
    The authors declare that no competing interests exist.
  13. David Meierhofer

    Max Planck Institute for Molecular Genetics, Berlin, Germany
    Competing interests
    The authors declare that no competing interests exist.
  14. Luca Cozzuto

    Centre for Genomic Regulation, Barcelona, Spain
    Competing interests
    The authors declare that no competing interests exist.
  15. Andreas Winterpacht

    Human Genetics, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
    Competing interests
    The authors declare that no competing interests exist.
  16. Luciano DiCroce

    Centre for Genomic Regulation, Barcelona, Spain
    Competing interests
    The authors declare that no competing interests exist.
  17. Jinrong Min

    Structural Genomics Consortium, Toronto, Canada
    Competing interests
    The authors declare that no competing interests exist.
  18. Hans Will

    Heinrich-Pette-Institute - Leibniz Institute for Experimental Virology, Hamburg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  19. Sarah Kinkley

    Max Planck Institute for Molecular Genetics, Berlin, Germany
    For correspondence
    kinkley@molgen.mpg.de
    Competing interests
    The authors declare that no competing interests exist.

Copyright

© 2016, Ho-Ryun et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,631
    views
  • 684
    downloads
  • 24
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Chung Ho-Ryun
  2. Chao Xu
  3. Alisa Fuchs
  4. Andreas Mund
  5. Martin Lange
  6. Hannah Staege
  7. Tobias Schubert
  8. Chuanbing Bian
  9. Ilona Dunkel
  10. Anton Eberharter
  11. Catherine Regnard
  12. Henrike Klinker
  13. David Meierhofer
  14. Luca Cozzuto
  15. Andreas Winterpacht
  16. Luciano DiCroce
  17. Jinrong Min
  18. Hans Will
  19. Sarah Kinkley
(2016)
PHF13 is a molecular reader and transcriptional co-regulator of H3K4me2/3
eLife 5:e10607.
https://doi.org/10.7554/eLife.10607

Share this article

https://doi.org/10.7554/eLife.10607

Further reading

    1. Structural Biology and Molecular Biophysics
    Giuseppe Deganutti, Ludovico Pipito ... Christopher Arthur Reynolds
    Research Article

    The structural basis for the pharmacology of human G protein-coupled receptors (GPCRs), the most abundant membrane proteins and the target of about 35% of approved drugs, is still a matter of intense study. What makes GPCRs challenging to study is the inherent flexibility and the metastable nature of interaction with extra- and intracellular partners that drive their effects. Here, we present a molecular dynamics (MD) adaptive sampling algorithm, namely multiple walker supervised molecular dynamics (mwSuMD), to address complex structural transitions involving GPCRs without energy input. We first report the binding and unbinding of the vasopressin peptide from its receptor V2. Successively, we present the complete transition of the glucagon-like peptide-1 receptor (GLP-1R) from inactive to active, agonist and Gs-bound state, and the guanosine diphosphate (GDP) release from Gs. To our knowledge, this is the first time the whole sequence of events leading from an inactive GPCR to the GDP release is simulated without any energy bias. We demonstrate that mwSuMD can address complex binding processes intrinsically linked to protein dynamics out of reach of classic MD.

    1. Structural Biology and Molecular Biophysics
    Mia L Abramsson, Robin A Corey ... Michael Landreh
    Research Article

    Integral membrane proteins carry out essential functions in the cell, and their activities are often modulated by specific protein-lipid interactions in the membrane. Here, we elucidate the intricate role of cardiolipin (CDL), a regulatory lipid, as a stabilizer of membrane proteins and their complexes. Using the in silico-designed model protein TMHC4_R (ROCKET) as a scaffold, we employ a combination of molecular dynamics simulations and native mass spectrometry to explore the protein features that facilitate preferential lipid interactions and mediate stabilization. We find that the spatial arrangement of positively charged residues as well as local conformational flexibility are factors that distinguish stabilizing from non-stabilizing CDL interactions. However, we also find that even in this controlled, artificial system, a clear-cut distinction between binding and stabilization is difficult to attain, revealing that overlapping lipid contacts can partially compensate for the effects of binding site mutations. Extending our insights to naturally occurring proteins, we identify a stabilizing CDL site within the E. coli rhomboid intramembrane protease GlpG and uncover its regulatory influence on enzyme substrate preference. In this work, we establish a framework for engineering functional lipid interactions, paving the way for the design of proteins with membrane-specific properties or functions.